WO2007108009A1 - A process for purification of topiramate - Google Patents

A process for purification of topiramate Download PDF

Info

Publication number
WO2007108009A1
WO2007108009A1 PCT/IN2007/000107 IN2007000107W WO2007108009A1 WO 2007108009 A1 WO2007108009 A1 WO 2007108009A1 IN 2007000107 W IN2007000107 W IN 2007000107W WO 2007108009 A1 WO2007108009 A1 WO 2007108009A1
Authority
WO
WIPO (PCT)
Prior art keywords
topiramate
purification
purity
water
solution
Prior art date
Application number
PCT/IN2007/000107
Other languages
French (fr)
Inventor
Pandurang Balwant Deshpande
Parven Kumar Luthra
Anand Kumar Pandey
Bhavin Prafulbhai Hamirani
Original Assignee
Alembic Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Limited filed Critical Alembic Limited
Publication of WO2007108009A1 publication Critical patent/WO2007108009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals

Definitions

  • the present invention relates to a process for purification of Topiramate of formula (I).
  • Topiramate is chemically known as 2, 3:4, 5-Bis-O-(1-methylethylidene)-1-O- sulfamoyl-beta-D-fructopyranose or 2, 3:4, 5-Bis-O-(1-methylethylidene)- beta-D- fructopyranose sulfamate, having molecular formula C1 2 H21NO8S and molecular weight 339.36.
  • the current pharmaceutical product containing this drug is being sold by Ortho McNeil using the tradename Topamax ® in the form of tablets.
  • Topiramate is sulfamate-substituted monosaccharide derivative which are useful in the treatment of epilepsy, obesity, bipolar disorder, neuropathic pain, migraine and smoking cessation.
  • Topiramate acts as a carbonate dehydratase inhibitor, sodium channel blocker, AMPA antagonist, GABA agonist and glutamate antagonist.
  • Topiramate is first disclosed in US Patent No. 4,513,006 which also discusses its process for preparation. The final product is recrystallized from a mixture of ethyl acetate and hexane. However this process for purification remains silent about purity and yield of Topiramate.
  • US Patent No. 5,387,700 which discloses the recrystallization of Topiramate by using ethanol: water mixture as solvent which requires base treatment. This patent also discloses crystallization by using n-hexane which does not give Topiramate with high purity and yield.
  • Topiramate Form I obtained by present invention is characterized by its XRD pattern as shown in Fig.1.
  • Fig. 1 represnts the powder X-ray diffraction (XRD) pattern of Topiramate Form I.
  • Another object of the present invention is to provide a process for the purification of Topiramate which is operationally simple, easy to handle and applicable at an industrial scale.
  • Yet another object of the present invention is to provide process for purification of ; Topiramate which comprises purification of Topiramate by treating Topiramate base with mixture of acetone and water.
  • present invention relates to a process for the purification of Topiramate comprising a step of treating Topiramate base with a mixture of acetone and water.
  • Crude Topiramate as used hereinabove is meant to include Topiramate is any form, or hydrate, solvate or their mixtures, or any state of purity.
  • treating refers to suspending, dissolving, washing, mixing, crystallizing or recrystallizing Topiramate in any of the solvent described above.
  • Topiramate Form I as prepared according to aspect of present invention is characterized by powder X-ray diffraction peaks at about 9.2, 12.1, 13.0, 15.3, 16.1 , 17.2, 19.9, 20.7, 21.1 , 24.5, 25.8, 29.3 and 32.8 ⁇ 0.2 degree two-theta.
  • Topiramate is dissolved in acetone at about 20 0 C to 35 0 C under stirring to obtain a solution. Water is added to said solution drop wise under stirring. The slurry was cooled to about 0 0 C to about 15°C and stirred for about 1 hour to about 4 hours. It is filtered, washed with water and dried to obtain pure crystalline form of Topiramate.
  • crude Topiramate is dissolved in acetone at about 20 0 C to 35 0 C under stirring to obtain a solution.
  • the said solution is added to chilled water in one lot.
  • the slurry is stirred for about 1 hour to about 4 hours at about chilled temperature to ambient temperature. It is filtered, washed with water and dried to obtain pure Topiramate Form.
  • purification refers to any method known to a person skilled in the art such as purification from single solvent or combination of solvents by dissolving the compound optionally at elevated temperature and precipitating the compound by cooling the solution or removing solvent from the solution or both. It further includes methods such as solvent/antisolvent or precipitation.
  • Topiramate Form I is isolated from reaction mass by conventional isolation procedure such as filtration, centrifugation, washing the wet cake and drying or by evaporation of solvent.
  • Topiramate (10g) was dissolved in acetone (20ml) at about 20 0 C to 35 0 C under stirring to obtain a solution. The said solution was added to chilled water (40 ml) in one lot.Topiramate was started to crystallize out. The slurry was stirred for 2 hour at about chilled temperature to ambient temperature. It was filtered, washed with water and dried to obtain pure form of Topiramate (8.4gm), purity of at least 99.5% (HPLC).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Saccharide Compounds (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)

Abstract

The present invention provides novel process for the preparation of Topiramate Form I which comprising purifying crude Topiramate base by treating the same with mixture of acetone and water to obtain topiramate of at least 99.5% purity.

Description

A PROCESS FOR PURIFICATION OF TOPIRAMATE FIELD OF INVENTION:
The present invention relates to a process for purification of Topiramate of formula (I).
Figure imgf000002_0001
BACKGROUND OF THE INVENTION:
Topiramate is chemically known as 2, 3:4, 5-Bis-O-(1-methylethylidene)-1-O- sulfamoyl-beta-D-fructopyranose or 2, 3:4, 5-Bis-O-(1-methylethylidene)- beta-D- fructopyranose sulfamate, having molecular formula C12H21NO8S and molecular weight 339.36. The current pharmaceutical product containing this drug is being sold by Ortho McNeil using the tradename Topamax® in the form of tablets.
Topiramate is sulfamate-substituted monosaccharide derivative which are useful in the treatment of epilepsy, obesity, bipolar disorder, neuropathic pain, migraine and smoking cessation. Topiramate acts as a carbonate dehydratase inhibitor, sodium channel blocker, AMPA antagonist, GABA agonist and glutamate antagonist.
Topiramate is first disclosed in US Patent No. 4,513,006 which also discusses its process for preparation. The final product is recrystallized from a mixture of ethyl acetate and hexane. However this process for purification remains silent about purity and yield of Topiramate. US Patent No. 5,387,700 which discloses the recrystallization of Topiramate by using ethanol: water mixture as solvent which requires base treatment. This patent also discloses crystallization by using n-hexane which does not give Topiramate with high purity and yield.
US application No. 2004/0038911 which discloses crystallization of Topiramate by using ethanol: water mixture or ethanol. However these processes also remain silent about purity and yield of Topiramate.
US application No. 2004/0215004 which discloses crystallization of Topiramate in water which requires acid, base treatment before crystallization.
It is observed that all the purification process for Topiramate in prior art are silent with respect to yield and purity and required acid, base treatment.
We have observed that all prior art gives identical form having XRD pattern substantially similar as shown in Fig.1. This form is designated as Form I for the purpose of this specification.
Topiramate Form I obtained by present invention is characterized by its XRD pattern as shown in Fig.1.
The present inventors have observed that this process of purification of Topiramate is operationally simple, easy to handle and easily applicable at an industrial scale.
Surprisingly present inventors have discovered another process for purification of Topiramate which comprises purification of Topiramate by treating Topiramate base with mixture of acetone and water. BRIEF DESCRIPTION OF THE ACCOMPANYING FIGURES:
Fig. 1 represnts the powder X-ray diffraction (XRD) pattern of Topiramate Form I.
OBJECTS OF THE INVENTION:
It is therefore an object of the invention to provide a process for the purification of Topiramate to obtain topiramate of at least 99.5% purity (by HPLC).
Another object of the present invention is to provide a process for the purification of Topiramate which is operationally simple, easy to handle and applicable at an industrial scale.
Yet another object of the present invention is to provide process for purification of ; Topiramate which comprises purification of Topiramate by treating Topiramate base with mixture of acetone and water.
SUMMARY OF THE INVENTION:
According to one aspect of present invention there is provided improved process for preparation of Topiramate Form I comprising steps of:
(i) dissolving crude Topiramate in acetone to form a solution;
(ϋ) addition of water to said solution;
(iii) cooling the suspension and stirring it;
(iv) isolating pure Topiramate Form I of at least 99.5% purity (by HPLC)..
According to another aspect of the present invention there is provided improved process for preparation of Topiramate Form I comprising steps of:
(i) dissolving crude Topiramate in acetone to form a solution
(ii) addition of said solution to chilled water
(iii) stirring the suspension
(iv) isolating pure Topiramate Form I of at least 99.5% purity (by HPLC). DETAILED DESCRIPTION OF THE INVENTION:
Accordingly, present invention relates to a process for the purification of Topiramate comprising a step of treating Topiramate base with a mixture of acetone and water.
The term "crude Topiramate" as used hereinabove is meant to include Topiramate is any form, or hydrate, solvate or their mixtures, or any state of purity. <-
The term "treating" as used hereinabove refers to suspending, dissolving, washing, mixing, crystallizing or recrystallizing Topiramate in any of the solvent described above.
Topiramate Form I as prepared according to aspect of present invention, is characterized by powder X-ray diffraction peaks at about 9.2, 12.1, 13.0, 15.3, 16.1 , 17.2, 19.9, 20.7, 21.1 , 24.5, 25.8, 29.3 and 32.8 ±0.2 degree two-theta.
Crude Topiramate is dissolved in acetone at about 20 0C to 35 0C under stirring to obtain a solution. Water is added to said solution drop wise under stirring. The slurry was cooled to about 0 0C to about 15°C and stirred for about 1 hour to about 4 hours. It is filtered, washed with water and dried to obtain pure crystalline form of Topiramate.
In another embodiment of the present invention, crude Topiramate is dissolved in acetone at about 20 0C to 35 0C under stirring to obtain a solution. The said solution is added to chilled water in one lot. The slurry is stirred for about 1 hour to about 4 hours at about chilled temperature to ambient temperature. It is filtered, washed with water and dried to obtain pure Topiramate Form.
The term "purification" refers to any method known to a person skilled in the art such as purification from single solvent or combination of solvents by dissolving the compound optionally at elevated temperature and precipitating the compound by cooling the solution or removing solvent from the solution or both. It further includes methods such as solvent/antisolvent or precipitation.
Topiramate Form I is isolated from reaction mass by conventional isolation procedure such as filtration, centrifugation, washing the wet cake and drying or by evaporation of solvent.
The process of the present invention is described by the following examples, which are illustrative only and should not be construed so as to limit the scope of the invention in any manner.
Crude Topiramate used in the examples is prepared according to methods reported in the literature and prior art.
Example 1 Preparation of pure form of Topiramate
Crude Topiramate (1Og) was dissolved in acetone (20ml) at about 20 0C to 35 0C under stirring to obtain a solution. Water (40 ml) was added to said solution drop wise under stirring. Topiramate crystallized out. The slurry was cooled to 10 0C to 15°C and stirred for 2 hour. It was filtered, washed with water and dried to obtain pure form of Topiramate (8.2 gm), purity of at least 99.5% (HPLC).
Example 2 Preparation of pure form of Topiramate
Crude Topiramate (10g) was dissolved in acetone (20ml) at about 20 0C to 35 0C under stirring to obtain a solution. The said solution was added to chilled water (40 ml) in one lot.Topiramate was started to crystallize out. The slurry was stirred for 2 hour at about chilled temperature to ambient temperature. It was filtered, washed with water and dried to obtain pure form of Topiramate (8.4gm), purity of at least 99.5% (HPLC).

Claims

1. A process for preparation of Topiramate Form I, comprising steps of. i. dissolving crude Topiramate in acetone; ii. addition of water to the solution obtained in step (i); iii. cooling the suspension; iv. isolating Topiramate Form I of at least 99.5% purity.
2. A process for preparation of Topiramate Form I, comprising steps of: i. dissolving crude Topiramate in acetone to form a solution; ii. addition of said solution to chilled water; iii. isolating pure Topiramate Form I of at least 99.5% purity.
3. The process according to any preceding claims, wherein the crude Topiramate used herein is any form, hydrate, clathrate, solvate or their mixtures and in any state of purity.
PCT/IN2007/000107 2006-03-17 2007-03-15 A process for purification of topiramate WO2007108009A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN371MU2006 2006-03-17
IN371/MUM/2006 2006-03-17

Publications (1)

Publication Number Publication Date
WO2007108009A1 true WO2007108009A1 (en) 2007-09-27

Family

ID=38325553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000107 WO2007108009A1 (en) 2006-03-17 2007-03-15 A process for purification of topiramate

Country Status (1)

Country Link
WO (1) WO2007108009A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387700A (en) * 1991-09-19 1995-02-07 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose and (1-methylcyclohexyl)methanol
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
EP1627881A1 (en) * 2004-08-19 2006-02-22 Helm AG Process for the preparation of topiramate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387700A (en) * 1991-09-19 1995-02-07 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose and (1-methylcyclohexyl)methanol
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
EP1627881A1 (en) * 2004-08-19 2006-02-22 Helm AG Process for the preparation of topiramate

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules

Similar Documents

Publication Publication Date Title
EP2125705A2 (en) Crystalline minocycline base and processes for its preparation
JP7160946B2 (en) (Thio)nicotinamide ribofuranoside salts and compositions, methods of preparation, and uses thereof
AU2011334928B2 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
AU2002241764A1 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
WO2014041566A2 (en) An improved process for the preparation of metformin hydrochloride
WO2008010231A2 (en) A process for the purification of topiramate
CN102850418B (en) A kind of crystallization and drying means preparing high purity azacitidine
WO2007108009A1 (en) A process for purification of topiramate
JP2018528233A (en) Process for producing indoline compounds and novel indoline salts
EP2341056B1 (en) Crystallizing method of erythromycin
US20120232258A1 (en) Process for the Preparation and Purification of Topiramate
WO2011015219A1 (en) Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers
WO2012070066A1 (en) Process for the preparation of taurolidine and its intermediates thereof
WO2020039449A1 (en) An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
WO2000035934A1 (en) Macrolide intermediates in the preparation of clarithromycin
AU2008298402B2 (en) Method for producing N-methacryloyl-4-cyano-3-trifluoromethylaniline
WO2002060873A1 (en) 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
RU2130942C1 (en) Method of preparing 3&#39;-azido-2&#39;,3&#39;-dideoxythymidine
US10011626B2 (en) Method for the purification of decitabine
EP1580194B1 (en) Method of obtaining polymorphic form i of finasteride
US6008413A (en) Process for recrystallizing 1,3-bis(aminophenoxy benzene)
KR20060110867A (en) Process for the preparation of doxifluridine
JPH051053A (en) New process for producing 6-(3-dimethylamino-propionyl) forskolin
JP2000178294A (en) Production of pentaacetyl-beta-d-glucose
ITMI20101078A1 (en) POLYMORFI OF FEXOFENADINA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736567

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07736567

Country of ref document: EP

Kind code of ref document: A1